- Email: [email protected]
4992271 Formulation for lipophilic IL-2 proteins
320
PATENT ABSTRACTS
4990497 ANTIFUNGAL
ANTIBIOTICS
Toshikazu Oki, Kyoichiro Saitoh, Kozo Tomatsu, Koji Tomita, Masataka Konishi, Takeo Miyaki, Mitsuaki Tsunakawa, Maki Nishio, Sakae ku, Yokohama, Japan Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.
4990596 SYNTHETIC PEPTIDE PRODUCING ANTIBODIES OF ENHANCED BINDING TO HUMAN LDH-C4 Erwin Goldberg assigned University
to Northwestern
A synthetic peptide producing antibodies of enhanced binding to the human C4 isozyme of lactate dehydrogenase (LDH-C4) is composed of amino acids corresponding to the 9 to 20 sequence of the human enzyme. The peptide can be used as the active component of an antifertility vaccine for women.
4992051 INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS MUTANTS, METHODS FOR THE PRODUCTION OF SAME AND METHODS FOR THE USE OF SAME Malon Kit, Saul Kit, Haruki Otsuka assigned to Novagene Inc; Baylor College of Medici Infectious bovine rhinotracheitis virus (bovine herpesvirus type 1) mutants containing deletion and/or insertion mutations in a major viral glycoprotein gene, such that no antigenic polypeptides encoded by the viral gene are produced, vaccines for infectious bovine rhinotrachetis containing the same, methods for the production of the same and methods for use of the same. Animals vaccinated with these mutants do not develop antibodies to the viral glycoprotein and
can be distinguished serologically from animals infected with infectious bovine rhinotracheitis virus field strains. 4992271 FORMULATION FOR LIPOPHILIC IL-2 PROTEINS Wolfgang H Hanisch, Peter M Fernandes, Terrance Taforo assigned to Cetus Corporation An improved process for recovering and purifying lipophilic recombinant proteins such as human beta-interferon and interleukin-2 from their hosts yields a protein preparation which may be formulated into a stable pharmaceutical composition having a therapeutically effective amount of the biologically active recombinant lipophilic protein dissolved in a non-toxic, inert, therapeutically compatible aqueous-based carrier medium at a pH of 6.8 to 7.8 which medium also contains a stabilizer for the protein, such as human serum albumin, normal serum albumin and human plasma protein fraction.
4992272 CANINE DISTEMPER VACCINE
VIRUS
Edmund P Bass, William H Kelsey, Michael D McFarland assigned to Diamond Scientific A vaccine composition for animals susceptible to infection by canine distemper virus. The vaccine comprises a small but immunologically effective amount of an inactivated canine distemper virus in combination with a non-toxic pharmaceutically acceptable immunologic adjuvant. A preferred method of inactivation of canine distemper virus by either exposure of the virus to an inactivating effective amount of binary ethyleneimine or alternatively exposure of the virus to long wavelength ultraviolet light in the presence of a furocoumarin.
4992273 ANTIGENS OF LEISHMANIA PARASITES Louis Monjour, Alberto Roseto, Armand Berneman, Marie-Claude Guillemin-Debons, Martine Domurado, George Peries, Paris, France
PATENT ABSTRACTS
4990497 ANTIFUNGAL
ANTIBIOTICS
Toshikazu Oki, Kyoichiro Saitoh, Kozo Tomatsu, Koji Tomita, Masataka Konishi, Takeo Miyaki, Mitsuaki Tsunakawa, Maki Nishio, Sakae ku, Yokohama, Japan Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.
4990596 SYNTHETIC PEPTIDE PRODUCING ANTIBODIES OF ENHANCED BINDING TO HUMAN LDH-C4 Erwin Goldberg assigned University
to Northwestern
A synthetic peptide producing antibodies of enhanced binding to the human C4 isozyme of lactate dehydrogenase (LDH-C4) is composed of amino acids corresponding to the 9 to 20 sequence of the human enzyme. The peptide can be used as the active component of an antifertility vaccine for women.
4992051 INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS MUTANTS, METHODS FOR THE PRODUCTION OF SAME AND METHODS FOR THE USE OF SAME Malon Kit, Saul Kit, Haruki Otsuka assigned to Novagene Inc; Baylor College of Medici Infectious bovine rhinotracheitis virus (bovine herpesvirus type 1) mutants containing deletion and/or insertion mutations in a major viral glycoprotein gene, such that no antigenic polypeptides encoded by the viral gene are produced, vaccines for infectious bovine rhinotrachetis containing the same, methods for the production of the same and methods for use of the same. Animals vaccinated with these mutants do not develop antibodies to the viral glycoprotein and
can be distinguished serologically from animals infected with infectious bovine rhinotracheitis virus field strains. 4992271 FORMULATION FOR LIPOPHILIC IL-2 PROTEINS Wolfgang H Hanisch, Peter M Fernandes, Terrance Taforo assigned to Cetus Corporation An improved process for recovering and purifying lipophilic recombinant proteins such as human beta-interferon and interleukin-2 from their hosts yields a protein preparation which may be formulated into a stable pharmaceutical composition having a therapeutically effective amount of the biologically active recombinant lipophilic protein dissolved in a non-toxic, inert, therapeutically compatible aqueous-based carrier medium at a pH of 6.8 to 7.8 which medium also contains a stabilizer for the protein, such as human serum albumin, normal serum albumin and human plasma protein fraction.
4992272 CANINE DISTEMPER VACCINE
VIRUS
Edmund P Bass, William H Kelsey, Michael D McFarland assigned to Diamond Scientific A vaccine composition for animals susceptible to infection by canine distemper virus. The vaccine comprises a small but immunologically effective amount of an inactivated canine distemper virus in combination with a non-toxic pharmaceutically acceptable immunologic adjuvant. A preferred method of inactivation of canine distemper virus by either exposure of the virus to an inactivating effective amount of binary ethyleneimine or alternatively exposure of the virus to long wavelength ultraviolet light in the presence of a furocoumarin.
4992273 ANTIGENS OF LEISHMANIA PARASITES Louis Monjour, Alberto Roseto, Armand Berneman, Marie-Claude Guillemin-Debons, Martine Domurado, George Peries, Paris, France